Adopting automated on-body injectors requires hospitals to adapt internal systems rather than simply stocking the medication. Institutions must establish physical workflows for two-nurse verification checks, manage distinct storage locations for device parts, and build specialized order templates within electronic health records.
Although trial data proved at-home on-body delivery maintains identical efficacy and pharmacokinetics to clinic dosing, adoption remains limited internationally. Expansion in the United States is currently hindered by the lack of mobile healthcare provider administration models and undefined pharmacy reimbursement pathways.
Transitioning multiple myeloma regimens to an on-body injector reduces clinic chair time from hours down to a median of thirteen minutes. In addition to improving workflow speed, the modality lowers infusion-related reaction rates and utilizes a retractable 30-gauge needle to mitigate needle-stick injuries.
